{"date":"2025-07-08","count":13,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-1783-2025-07-08-1824-54swv6","company_id":"1783","company":"和康生","market":"上市","industry":"生技醫療","date":"2025-07-08","time":"18:24:26","subject":"公告本公司法人董事改派代表人","clause":"第6款","fact_date":"2025-07-08","cite_as":"公開資訊觀測站重大訊息：和康生（1783），2025-07-08 18:24，「公告本公司法人董事改派代表人」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4728-2025-07-08-1802-1evumyw","company_id":"4728","company":"雙美","market":"上櫃","industry":"生技醫療","date":"2025-07-08","time":"18:02:27","subject":"公告更正本公司113年度年報部分內容。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：雙美（4728），2025-07-08 18:02，「公告更正本公司113年度年報部分內容。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4120-2025-07-08-1741-yevnji","company_id":"4120","company":"友華","market":"上櫃","industry":"生技醫療","date":"2025-07-08","time":"17:41:17","subject":"代重要子公司Cyntec公告董事會決議通過取得 Rakuten Medical Inc.優先股權案","clause":"第20款","fact_date":"2025-07-08","cite_as":"公開資訊觀測站重大訊息：友華（4120），2025-07-08 17:41，「代重要子公司Cyntec公告董事會決議通過取得 Rakuten Medical Inc.優先股權案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4120-2025-07-08-1740-1k5ealt","company_id":"4120","company":"友華","market":"上櫃","industry":"生技醫療","date":"2025-07-08","time":"17:40:57","subject":"公告本公司最近一年累積處分有價證券金額達本公司實收資本額20%之公告標準","clause":"第20款","fact_date":"2025-07-08","cite_as":"公開資訊觀測站重大訊息：友華（4120），2025-07-08 17:40，「公告本公司最近一年累積處分有價證券金額達本公司實收資本額20%之公告標準」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6589-2025-07-08-1725-1dq7xmy","company_id":"6589","company":"台康生技","market":"上市","industry":"生技醫療","date":"2025-07-08","time":"17:25:24","subject":"本公司研發中產品EG1206A(pertuzumab生物相似藥)，獲得阿根廷國家藥品、食品暨醫療科技管理局同意進行第三期臨床試驗","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：台康生技（6589），2025-07-08 17:25，「本公司研發中產品EG1206A(pertuzumab生物相似藥)，獲得阿根廷國家藥品、食品暨醫療科技管理局同意進行第三期」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6758-2025-07-08-1725-1rmha3g","company_id":"6758","company":"冠亞","market":"興櫃","industry":"生技醫療","date":"2025-07-08","time":"17:25:01","subject":"公告本公司董事長決議訂定113年度現金股利除息基準日","clause":"第31款","fact_date":"2025-07-08","cite_as":"公開資訊觀測站重大訊息：冠亞（6758），2025-07-08 17:25，「公告本公司董事長決議訂定113年度現金股利除息基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6620-2025-07-08-1714-1sbgsf2","company_id":"6620","company":"漢達","market":"上櫃","industry":"生技醫療","date":"2025-07-08","time":"17:14:18","subject":"代子公司Handa Pharma, Inc公告重要營運主管異動案","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：漢達（6620），2025-07-08 17:14，「代子公司Handa Pharma, Inc公告重要營運主管異動案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6876-2025-07-08-1701-in3r67","company_id":"6876","company":"朗齊生醫*","market":"興櫃","industry":"生技醫療","date":"2025-07-08","time":"17:01:49","subject":"公告本公司董事會決議通過對100％投資之SAMOA子公司現金增資","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：朗齊生醫*（6876），2025-07-08 17:01，「公告本公司董事會決議通過對100％投資之SAMOA子公司現金增資」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6876-2025-07-08-1650-zc9ex6","company_id":"6876","company":"朗齊生醫*","market":"興櫃","industry":"生技醫療","date":"2025-07-08","time":"16:50:03","subject":"公告本公司董事會通過執行長暨總經理任命案","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：朗齊生醫*（6876），2025-07-08 16:50，「公告本公司董事會通過執行長暨總經理任命案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6796-2025-07-08-1523-ym49li","company_id":"6796","company":"晉弘","market":"上市","industry":"生技醫療","date":"2025-07-08","time":"15:23:01","subject":"本公司受邀參加中國信託證券舉辦之法人說明會","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：晉弘（6796），2025-07-08 15:23，「本公司受邀參加中國信託證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6469-2025-07-08-1431-way5t9","company_id":"6469","company":"大樹","market":"上櫃","industry":"生技醫療","date":"2025-07-08","time":"14:31:41","subject":"公告本公司國內第三次無擔保轉換公司債完成訂價","clause":"第53款","fact_date":"2025-07-08","cite_as":"公開資訊觀測站重大訊息：大樹（6469），2025-07-08 14:31，「公告本公司國內第三次無擔保轉換公司債完成訂價」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4911-2025-07-08-1428-i4eezk","company_id":"4911","company":"德英","market":"上櫃","industry":"生技醫療","date":"2025-07-08","time":"14:28:37","subject":"公告本公司董事會決議除權息基準日等相關事宜","clause":"第14款","fact_date":"2025-07-08","cite_as":"公開資訊觀測站重大訊息：德英（4911），2025-07-08 14:28，「公告本公司董事會決議除權息基準日等相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6543-2025-07-08-1340-d31unw","company_id":"6543","company":"普惠醫工","market":"興櫃","industry":"生技醫療","date":"2025-07-08","time":"13:40:55","subject":"更新1140701代重要子公司越南普惠醫療工藝責任有限公司公告(修正付款期間)","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：普惠醫工（6543），2025-07-08 13:40，「更新1140701代重要子公司越南普惠醫療工藝責任有限公司公告(修正付款期間)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}